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Paraoxonase 1 (PON1) activity has been implicated
in the pathogenesis of atherosclerosis [1]. PON1 is a
calcium-dependent esterase that is exclusively bound
to the apolipoprotein A1 (apoA1) containing high-
density lipoprotein (HDL) fraction in serum [2]. Oxi-
dized low-density lipoproteins (LDL) has been shown
to be a casual pathogenic factor in the development
of atherosclerosis. In vitro studies showed that PON1
prevents accumulation of lipoperoxides in LDL [3].
Studies have demonstrated low PON1 activity in
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The objective of this study was to investigate apolipoprotein B (apoB) carbonyl content as a param-
eter for studying low-density lipoprotein (LDL) oxidation in coronary artery disease (CAD) risk
assessment and to explore the relationship between apoB carbonyl content (an index of protein
oxidation) and paraoxonase 1 (PON1) activity in CAD patients and controls. A total of 200 patients
suffering from CAD and 150 normal individuals were included in the present study. CAD patients
were classified into two groups on the basis of associated risk factors (diabetes mellitus, hyper-
tension): group 1 (n = 120; CAD patients with associated risk factors) and group 2 (n = 80; CAD
patients with no associated risk factors). All subjects were assayed for apoB carbonyl content,
LDL-malondialdehyde (LDL-MDA), PON1 activity, and lipid and apolipoprotein levels. ApoB
carbonyl content was significantly (p < 0.01) raised in CAD patients (with or without associated
risk factors) as compared to controls. Patients also had relatively raised LDL-MDA levels. Serum
PON1 activity was significantly low (p < 0.01) in CAD patients. A significantly (p < 0.01) negative
coefficient of correlation was observed between apoB carbonyl content and PON1 activity in both
patients and controls. CAD patients with associated risk factors had highly raised (p < 0.01) apoB
carbonyl content and considerably depressed PON1 activity compared to those with no associ-
ated risk factors. LDL-MDA levels did not differ significantly (p > 0.05) between the two groups.
CAD patients in group 1 also had significantly raised apoB levels and low HDL-cholesterol and
apoA1 levels as compared to patients in group 2, while the other lipid variables did not show any
significant difference. A significantly negative coefficient of correlation was observed between
apoB carbonyl content and PON1 activity in both patients and controls. This is a new piece of
information that needs to be further explored. Quantification of apoB carbonyl content may act
as a suitable parameter for studying LDL oxidation in the evaluation of CAD risk, especially
when confounding risk factors are present.
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patients with carotid artery disease [3], coronary heart
disease [4] and myocardial infarction [1]. Low serum
PON1 activity was also reported in smokers [5] and
diabetics [6]. All these studies either independently
reported the effects of low PON1 activity or attempted
to relate PON1 activity with LDL oxidation. But oxi-
dation of LDL has been mainly studied in terms of
lipid peroxidation or by measuring its resistance time
to oxidation. After reviewing the existing literature, it
seemed that measuring lipid peroxidation parame-
ters in LDL does not always provide significant infor-
mation regarding the oxidative status. Kruijssen et al
[7] found higher maximum diene levels in a control
population compared with coronary artery disease
(CAD) patients. It was stated in the same study that
diene production may not be a suitable parameter for
studying LDL oxidation as a risk factor of CAD.
Hence, we were interested in quantifying the apoB
carbonyl content in LDL, which is taken as an index of
protein oxidation. This may serve as a better parameter
for assessing LDL oxidation in CAD patients. We also
aimed at exploring the relationship between apoB
carbonyl content and PON1 activity in CAD patients
and control subjects.
MATERIALS AND METHODS
This study included 200 individuals with established
CAD (mean age, 53 ± 10 years) and 150 healthy indi-
viduals as controls (mean age, 52 ± 8 years). CAD
patients were recruited from the wards/outpatient
departments of Guru Nanak Dev Hospital and ESI
Hospital, Amritsar, India. Diagnosis of CAD was done
on the basis of clinical symptoms, electrocardiograph
(ECG) changes, and stress test by the cardiologists.
Patients were also subjected to angiography if required.
A questionnaire was prepared containing the neces-
sary details of the patients, i.e. associated risk factors
(diabetes mellitus, hypertension), history of myocar-
dial infarction (MI), smoking habits, alcohol intake,
family history, and use of cardiac/antihyperten-
sive/hypoglycemic drugs. Patients with thyroid or
renal disease, any acute infection or any other con-
comitant disease, and women on oral contraceptives
were excluded. Patients on lipid-lowering drugs or
antioxidants were also excluded from the study
because of a possible influence of these agents on LDL
oxidation.
A control group comprising healthy individuals
was recruited from the general population. They nei-
ther had any evident symptom of CAD nor a past his-
tory of the disease. Still, these subjects were subjected
by the treating experts to ECG, stress test, and angiog-
raphy wherever possible to confirm their clinical con-
dition. Control subjects taking antioxidants in the form
of vitamins C, E or B-complex formulations supple-
mented with antioxidants were excluded. A detailed
performa containing their smoking and alcohol status,
family history, history of MI, blood pressure, and use of
antihypertensive drugs and other drugs (excluding
lipid lowering) was also recorded. Hypertension were
defined as blood pressure ≥ 140/90 mmHg. Diabetics
were defined as those subjects having fasting blood
glucose levels > 7.8 mmol/L. In our patient population
studied, diabetes and hypertension were the two most
frequent associated risk factors. Smoking and alcohol
status was self-reported. CAD patients had quit smok-
ing and alcohol intake on the advice of their treating
experts (mean time, 1.5 years). They were taken as ex-
smokers and ex-alcoholics. Informed consent was
obtained from all participants. CAD patients were com-
pared with controls after matching for age and sex.
Blood collection
Blood samples were taken after 12-hour overnight fast
from healthy individuals and CAD patients. Samples
were allowed to stand for 30 minutes at room tem-
perature (protected from ultraviolet light). Serum was
separated after centrifugation at 2,000g for 10 minutes
and stored at −20oC until analysis. ApoB carbonyl con-
tent (LDL protein oxidation), LDL-malondialdehyde
(LDL-MDA) levels (LDL lipid peroxidation), PON1
activity, serum apoB, apoA1, total cholesterol, triglyc-
erides, HDL cholesterol and LDL cholesterol levels
were determined for all subjects. We tried to deter-
mine the oxidation parameters in the serum on the
day the blood samples were drawn to avoid spon-
taneous LDL oxidation, but where storage was needed
to be done, butylated hydroxytoluene (BHT) was
added in the samples to check the spontaneous oxi-
dation of LDL.
Precipitation of LDL
Serum LDL of all samples was isolated by precipita-
tion method [8]. The precipitation buffer consisted 
of 0.064 M trisodium citrate adjusted to pH 5.05 
and contained 50,000 IU/L heparin. The insoluble
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lipoproteins were sedimented by centrifugation at
1,000g for 10 minutes. The pellet was resuspended 
in 1 mL of 0.1 M sodium phosphate buffer pH 7.4, 
containing 0.9% NaCl.
Estimation of apoB carbonyl content
ApoB carbonyl content was estimated by the method
of Yan et al [9]. Ten millimolar concentration of dini-
trophenylhydrazine (DNPH) in 2 M HCl was added
to isolated LDL solution in a centrifuge tube. The
contents were incubated at room temperature for 
1 hour. Then 0.6 mL of denaturing buffer (0.15 M
sodium phosphate buffer, pH 6.8 containing 3%
sodium dodecyl sulfate) was added and tubes were
allowed to vortex for 1 minute. After mixing, an equal
volume of ethanol and heptane mixture was added
and the contents were mixed again. The tubes were
centrifuged at 1,000g for 5 minutes. LDL was recov-
ered from the interface and was washed three times
with ethanol ethyl acetate (1:1 v/v) mixture. Each
DNPH sample was dissolved in denaturing buffer
and was scanned from 320 to 410 nm. The peak
absorbance was used to calculate protein carbonyls
with extinction coefficient 22,000 M−1 cm−1. Results
were expressed as nmoles carbonyl/mg LDL protein.
Measurement of MDA level of LDL
LDL-MDA levels were estimated by the method of
Beuge and Aust [10]. One milliliter trichloroacetic acid
and thiobarbituric acid (TCA-TBA) reagent was added
to the isolated LDL dissolved in sodium phosphate
buffer (0.15 M, pH 6.8). The contents were mixed and
kept in a boiling water bath for 30 minutes. The floc-
culate precipitates were settled by centrifuging at
3,000 rpm for 10 minutes. The intensity of the light-
pink-colored clear supernatant was measured at 535nm
against a blank containing normal saline instead of the
sample. The molar extinction coefficient of the MDA
used was 1.56 × 105 M−1 cm−1. Results were expressed
as nmoles MDA/mg LDL protein.
Assay of PON1 activity
PON1 activity was assessed by the method of Furlong
et al [11]. Ten microliter serum was added to 200μL of
Tris HCl buffer (100 mM; pH 8.0) containing calcium
chloride (2 mM) and paraoxon (5 mM) in wells of
microtiter plates. The contents were mixed gently and
the microtiter plate was read immediately at 405 nm
to establish zero time values. Readings were taken at
2-minute intervals for 10 minutes. Nonenzymatic
hydrolysis was subtracted from the total rate of hy-
drolysis. The quantity of p-nitrophenol formed was
calculated by taking molar extinction coefficient of 
p-nitrophenol to be 17,100 M−1 cm−1 at pH 8.0. One unit
of PON1 activity was defined as 1μmol of p-nitrophe-
nol released per liter serum per minute.
Other laboratory determinations
The protein concentration of each isolated LDL sample
was determined by the protocol of Lowry et al [12].
Total cholesterol levels were estimated by the method
of Zlatkis et al [13] as modified by Zak. HDL cho-
lesterol was determined after precipitation of apoB-
containing lipoproteins by phosphotungstic acid/
MgCl2 [14]. Triglycerides were measured enzymati-
cally using kits from Biotec India Pvt Ltd. LDL-C was
estimated using Friedwald equation [15]. Fasting
blood sugar levels were estimated with glucose-oxidase
method with commercially provided kits. Reference
sera for lipid and lipoprotein cholesterol were pro-
cured from Randox India Pvt Ltd. ApoB and A1 lev-
els were estimated with commercially available kits
(Diasys India Pvt Ltd) using immunoturbidimetric
method. The reagents and calibrators were claimed to
be in accordance with WHO international reference
material. Results were expressed as mg/dL.
Statistical analysis
Statistical analysis was done using student’s t test.
Coefficients of correlation between different parame-
ters were calculated. Level of significance was deter-
mined at p < 0.05.
RESULTS
Table 1 indicates the baseline clinical data of the sub-
jects. There was no significant difference in the basal
metabolic index (BMI) and age of CAD patients and
controls. None in the control group had diabetes or
impaired glucose tolerance. Sixty percent of the total
CAD patients had diabetes mellitus. Hypertension
was observed to be more prevalent among patients.
Ten percent of the controls were moderate alcohol
consumers but none was a smoker (not shown). CAD
patients had quit smoking and alcohol intake (average
time, 1.5 years). Hence, we could not take smoking
and alcohol intake as major considerations as far as
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the comparison with controls is concerned. Otherwise,
smoking is a well-known cardiovascular risk factor.
Lipid and apolipoprotein levels of CAD patients
were compared with those of normal subjects. The
data for males and females were dealt with sepa-
rately. Serum total cholesterol, LDL-C, and apoB levels
were relatively low in normal females as compared 
to normal males while females had relatively raised
triglyceride, HDL-C, and apoA1 levels. A similar trend
was observed in CAD patients. Overall total choles-
terol, triglycerides, and LDL cholesterol levels were
raised in CAD patients and HDL cholesterol levels
were significantly low (p < 0.01). Apo levels were also
deranged in patients when compared with controls.
Patients had significantly raised (p < 0.01) serum
apoB levels and low apoA1 levels.
ApoB carbonyl content was significantly raised 
(p < 0.01) in CAD patients as compared with controls
(Figure). Patients also had relatively raised LDL-MDA
levels. Serum PON1 activity was significantly lower
(p < 0.01) in patients compared with normal individu-
als. A significant negative coefficient of correlation
(r = − 0.71) was observed between apoB carbonyl con-
tent and serum PON1 activity. PON1 activity was also
inversely related to LDL-MDA levels. A weak posi-
tive coefficient of correlation (p > 0.05) was observed
between apoB carbonyl content and LDL-MDA lev-
els. A significant negative coefficient of correlation
Table 1. Clinical and biochemical features of the study participants
Parameters
Controls CAD patients
Males Females Males Females
Number 66 84 90 110
Age (yr) 54 ± 7 51 ± 8 55 ± 9* 52 ± 8*
BMI (kg/m2) 26 ± 2 27.2 ± 2.3 27.6 ± 3.1* 26.4 ± 3.3*
Diabetes mellitus (n) Nil Nil 85 35
Hypertension (n) 6 9 22 38
Use of cardiac/hypoglycemic/ 4 8 75 65
antihypertensive drugs (n)
Total cholesterol (mg/dL) 188 ± 11.6 175 ± 11.4 230 ± 13.6† 215 ± 13.9†
Triglycerides (mg/L) 136 ± 10.8 148 ± 10.5 185 ± 12.5† 200 ± 12.7†
LDL cholesterol (mg/dL) 118 ± 11.8 102 ± 12.0 154 ± 11.9† 133 ± 12.2†
HDL cholesterol (mg/dL) 44 ± 10.0 47 ± 9.8 39.6 ± 10.0† 42 ± 10.3†
ApoB (mg/dL) 86 ± 13.0 80 ± 13.2 162 ± 12.5† 150 ± 12.3†
ApoA1 (mg/dL) 152 ± 12.2 160 ± 12.4 129 ± 12.3† 136 ± 12.5†
*p > 0.05 (difference between CAD patients and controls; males vs. males and females vs. females); †p < 0.01 (difference between CAD
patients and controls; males vs. males and females vs. females). CAD = coronary artery disease; BMI = body mass index; LDL = low-
density lipoprotein; HDL = high-density lipoprotein; apo = apolipoprotein.
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(r = − 0.60) between PON1 activity and apoB carbonyl
content was also observed in control subjects.
Patients in group 1 had significantly raised apoB
carbonyl content and depressed PON1 activity as
compared to patients in group 2 (Table 2). But LDL-
MDA levels did not differ significantly between the
two groups. In group 1 patients, coefficient of cor-
relation between serum PON1 activity and apoB 
carbonyl content was −0.65, while it was −0.63 in
group 2 patients. Group 1 patients also had relatively
increased apoB and low HDL-C and apoA1 levels as
compared with patients in group 2 (CAD patients
with no associated risk factors). But other lipid vari-
ables, i.e. total cholesterol, triglycerides, and LDL cho-
lesterol levels did not show any significant difference
(p > 0.05).
Seventy percent of patients were on treatment (ex-
cluding lipid lowering) as per their clinical conditions.
They had relatively low apoB carbonyl content and
high PON1 activity as compared with those who were
not on any regular treatment (Table 3). Patients on treat-
ment also had relatively low LDL-MDA levels and
improved lipid and apolipoprotein values, but the
difference was not statistically significant (p > 0.05).
DISCUSSION
There is considerable evidence that oxidized LDL has
been implicated in the pathogenesis of CAD [16,17].
Oxidation of LDL has been mainly assessed in terms
of its lipid peroxidation, which may not always be
informative for CAD risk assessment. Therefore, we
attempted to study LDL oxidation by quantifying its
apoB carbonyl content (an index of protein oxidation)
in addition to LDL-MDA levels to get a more com-
parative view. Both lipid peroxidation-dependent
and -independent mechanisms have been considered
Table 2. ApoB carbonyl content, LDL-MDA, PON1 activity, lipid, and apolipoprotein levels
Parameters Group 1* (n = 120) Group 2† (n = 80)
ApoB carbonyl content 3.1 ± 0.50 2.0 ± 0.71‡
(nmol/mg LDL protein)
LDL-MDA (nmol/mg LDL protein) 0.33 ± 0.08 0.31 ± 0.07
PON1 activity (μmol PNP released/min/L) 130 ± 11.2 172 ± 12.1‡
Total cholesterol (mg/dL) 210 ± 12.4 208 ± 12.1
Triglycerides (mg/dL) 220 ± 11.4 225 ± 11.8
LDL cholesterol (mg/dL) 126 ± 12.1 126 ± 12.3
HDL cholesterol (mg/dL) 37 ± 9.1 40 ± 8.6‡
ApoB (mg/dL) 158 ± 12.0 148 ± 11.5‡
ApoA1 (mg/dL) 110 ± 11.1 128 ± 11.9‡
*CAD patients with associated risk factors (diabetes mellitus, hypertension); †CAD patients with no associated risk factors; ‡p < 0.01
(comparison between two groups). Apo = apolipoprotein; LDL-MDA = low-density lipoprotein-malondialdehyde; PON1 = paraox-
onase 1; HDL = high-density lipoprotein.
Table 3. Effect of requisite treatment on lipid profile and related parameters of CAD patients 
Parameters
CAD patients not on CAD patients on requisite
requisite treatment (n = 60) treatment (n = 140)
ApoB carbonyl content (nmol/mg LDL protein) 3.2 ± 0.57 3.0 ± 0.54*
PON1 activity (μmol PNP released/min/L) 169 ± 12.6 178 ± 12.4*
LDL-MDA (nmol/mL) 0.32 ± 0.06 0.30 ± 0.08*
Total cholesterol (mg/dL) 215 ± 12.2 208 ± 12.6*
Triglycerides (mg/dL) 218 ± 12.4 215 ± 12.2*
LDL cholesterol (mg/dL) 131 ± 12.1 124 ± 11.9*
HDL cholesterol (mg/dL) 39.6 ± 10.0 41 ± 10.2*
ApoB (mg/dL) 154 ± 12.2 150 ± 12.4*
ApoA1 (mg/dL) 111 ± 12.6 115 ± 12.3*
*p > 0.05. Requisite treatment = use of cardiac/hypoglycemic/antihypertensive drugs; apo = apolipoprotein; PON1 = paraoxonase 1;
LDL-MDA = low-density lipoprotein-malondialdehyde; HDL = high-density lipoprotein.
to be responsible for the oxidation of apoB. ApoB 
carbonyl content was significantly raised in LDL of
CAD patients compared with that of normal subjects.
Patients also had relatively raised LDL-MDA levels.
PON1 is an antioxidative enzyme associated with HDL
in human serum. The activity of this enzyme was
considerably reduced in CAD patients compared with
controls. Similar results regarding increased LDL lipid
peroxidation and reduced PON1 activity have been
reported in other studies [1,18]. PON1 has been
reported to destroy lipid peroxides, thus imparting
protection to LDL against oxidation, although its phy-
siologic substrate is yet uncertain. Significantly low
PON1 activity in patients indicated their reduced abil-
ity to protect LDL from oxidation resulting in increased
LDL protein and lipid peroxidation.
A new piece of information gained from the pres-
ent investigation was that a significant negative cor-
relation was observed between apoB carbonyl content
and PON1 activity in both patients and controls. The
relationship between apoB carbonyl content and LDL-
MDA levels was weakly positive. These results indi-
cate that the oxidative modification of apoB may not
be solely as a result of LDL lipid peroxidation but the
other lipid peroxidation-independent mechanisms may
also promote apoB oxidation. This was supported by
the observation that apoB oxidation far exceeds that
of LDL-MDA levels (Figure). Free radicals may play
an important role in the oxidation of apoB and for
this very reason, controls were also shown to have an
inverse relation between apoB carbonyl content and
PON1 activity independent of LDL-MDA levels. The
presence of oxidative stress even in the normal human
body cannot be ruled out. This is just a preliminary
observation and needs further confirmation. CAD
patients also had disturbed lipid and apolipoprotein
levels but no significant relation was observed between
these parameters and the apoB carbonyl content.
Although several risk factors of CAD were present,
diabetes mellitus and hypertension were seen to be
more prevalent in our patient population. CAD patients
suffering from these associated risk factors had sig-
nificantly raised apoB carbonyl content and consider-
ably low PON1 activity as compared to CAD patients
having no associated risk. But LDL-MDA levels did not
differ significantly between the two groups. This is
again indicative of various other factors responsible for
apoB oxidation besides lipid peroxidation, possibly
the role of free radicals in causing direct injury to apoB
leading to its oxidation. But the exact mechanism and
factors are yet to be explored. The presence of associ-
ated risk factors may further enhance oxidative stress.
Diabetes is associated with increased oxidative stress,
which may promote apoB oxidation via free radicals
besides lipid peroxidation-dependent mechanisms.
Low PON1 activity has been reported in diabetics by
other workers [6].
Serum apoB levels were significantly raised and
apoA1 and HDL-C levels were considerably low in
CAD patients with associated risk factors as compared
to those having no associated risk factors. This was a
mutual comparison, otherwise, lipid and apolipopro-
tein levels were disturbed in patients (with or without
the associated risk factors) as compared to normal
subjects. Every risk factor is associated with its own
intrinsic pathology and metabolic disturbances and
the risk increases with the addition of each risk fac-
tor. This increased risk and severity of CAD can be
well assessed by the quantification of apoB carbonyl
content. Low apoA1 and HDL-C levels may be
indicative of disturbed lipid-protein environment,
which is essential for the efficient function of PON1
enzyme. CAD patients who were on some kind of reg-
ular treatment (excluding lipid-lowering drugs) were
having quantitatively less LDL oxidation and improved
lipid and apolipoprotein levels as compared to those
who were not on any regular treatment (Table 3). 
But the difference was not statistically significant.
Treatment and lifestyle modification through their
individual mechanisms reduce oxidative stress, but
the time period could vary and significant improve-
ment might appear later. We have not explored the
relation between the type of drug used and apoB 
oxidation and other parameters such as lipid and
apolipoprotein levels or PON1 activity. This needs a
separate study. We did not take alcohol and smoking
status as major considerations because the patients
were ex-smokers and ex-alcoholics and the separated
data did not provide any significant information.
Second, smokers and ex-alcoholics were not pure
smokers and alcoholics but were suffering from various
risk factors. Hence, the individual effect of smoking and
alcohol intake and also of diabetes or hypertension
on apoB carbonyl content could not be determined.
CAD is such a complicated disease that it is associ-
ated with interrelated pathologies and the frequency
of the associated risk factors is always more. In our
small study too, the majority of patients were suffering
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from associated risk factors (n = 120/200). Since bio-
chemical parameters were relatively more disturbed in
CAD patients with associated risk factors (group 1)
as compared with those in group 2, the risk of acute
coronary events might be more in these patients. 
In conclusion, an inverse relationship was observed
between PON1 activity and apoB carbonyl content 
in both patients and controls. Quantification of apoB
carbonyl content may act as suitable parameter to study
LDL oxidation for CAD risk assessment, especially
when other confounding risk factors are present. It is
actually the modified apoB moiety which is recognized
by scavenger receptors on macrophages to form foam
cells and not the lipid moiety in LDL [19].
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